MD BIOSCIENCES LAUNCHES NEUROLOGY DISCOVERY SERVICES.MD Biosciences, Herzelia-Pituah, Israel, a global biotechnology company focused in inflammations research, has expanded its Israel facility with the launch of its Neurology Discovery Services See service discovery. . The expanded laboratory in Israel provides the necessary capacity to accommodate the company's growing service portfolio, adding additional models for Multiple Sclerosis and launching new models for Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. , Nociception, Neuropathic neuropathic /neu·ro·path·ic/ (-path´ik) pertaining to or characterized by neuropathy. neuropathic pertaining to disease of the nervous system. and Inflammatory Pain. The rising number of pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. working within drug discovery and the strong emphasis on outsourcing increases MD Biosciences market potential. MD Biosciences launched its operations in 1998 with a focus in rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. products and services and has since added the Inflammations Discovery Service to include a broad range of models for RA, Asthma, IBD/Crohn's, Diabetes and MS along with the Senerga Platform for mechanism of action studies. "The launch of the Neurology Discovery Services laboratory in Israel directly compliments and strengthens the resources available to MD Biosciences' clients by providing a range of solutions for Neurological Diseases. This capability, together with our strong service portfolio from the Inflammations Discovery Service, will strengthen MD Biosciences' position even further, putting us at the cutting edge of drug discovery contract research," commented Eddie Moradian, PhD. and managing director. Dr Sigal Meilin, having extensive background and experience in the design and performance of neurological disease models, joins MD Biosciences Israel as the director of the Neurology Discovery Services. Dr Meilin received her PhD from the University of Bar Ilan, Israel, and performed post-doctoral research related to Alzheimer's disease and inflammation at the Tel Aviv University Tel Aviv University (TAU, אוניברסיטת תל־אביב, את"א) is Israel's largest on-site university. . Prior to joining MD Biosciences, Dr. Meilin was associate director of pharmacology and head of histology histology (hĭstŏl`əjē), study of the groups of specialized cells called tissues that are found in most multicellular plants and animals. at an innovative drug discovery firm in Israel. About MD Biosciences MD Biosciences provides the most advanced products and pre-clinical services for pharmaceutical and biotechnology companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories specialized laboratory A type of reference lab dedicated to a particular type of 'esoteric' testing–eg, allergy, coagulation, drugs–especially drugs of abuse, endocrinology, genetics, paternity, virology, etc. Cf Reference laboratory. located in Minnesota, Glasgow, and Israel. A panel of internationally recognized scientific experts provides pharmaceutical and biotechnology companies' in-depth expertise and technologies to tackle problems and provide total drug discovery solutions, enabling smarter results faster. For more information, visit http://www.mdbiosciences.com or call 651/641-1770. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion